APP and Alzheimer disease: If FLG was competitively bound to BACE1 or the interaction could lead to a decrease in BACE1 activity, then the competitive binding of APP to BACE1 would be decreased, leading to a reduction in Aβ42 produced by hydrolysis, which can alleviate the symptoms of AD.